Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets

The treatment options in multiple myeloma (MM) has changed dramatically over the past decade with the development of novel agents such as proteasome inhibitors (PIs); bortezomib and immunomodulatory drugs (IMiDs); thalidomide, and lenalidomide which revealed high efficacy and improvement of overall...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology 2019, Vol.2019 (2019), p.1-10
Main Authors: Nishida, Hiroko, Yamada, Taketo
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Antimitotic agents
Antineoplastic agents
B cells
Biopharmaceutics
Cancer
Cell adhesion & migration
Chronic illnesses
Clinical trials
Cytotoxicity
Drug dosages
FDA approval
Glycoproteins
Immunotherapy
Inhibitor drugs
Leukemia
Lymphoma
Monoclonal antibodies
Multiple myeloma
Plasma
Review
Signal transduction
T cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The treatment options in multiple myeloma (MM) has changed dramatically over the past decade with the development of novel agents such as proteasome inhibitors (PIs); bortezomib and immunomodulatory drugs (IMiDs); thalidomide, and lenalidomide which revealed high efficacy and improvement of overall survival (OS) in MM patients. However, despite these progresses, most patients relapse and become eventually refractory to these therapies. Thus, the development of novel, targeted immunotherapies has been pursued aggressively. Recently, next-generation PIs; carfilzomib and ixazomib, IMiD; pomalidomide, histone deacetylase inhibitor (HDADi); panobinostat and monoclonal antibodies (MoAbs); and elotuzumab and daratumumab have emerged, and especially, combination of mAbs plus novel agents has led to dramatic improvements in the outcome of MM patients. The field of immune therapies has been accelerating in the treatment of hematological malignancies and has also taken center stage in MM. This review focuses on an overview of current status of novel MoAb therapy including bispecific T-cell engager (BiTE) antibody (BsAb), antibody-drug conjugate (ADC), and chimeric antigen receptor (CAR) T cells, in relapsed or refractory MM (RRMM). Lastly, investigational novel MoAb-based therapy to overcome immunotherapy resistance in MM is shown.
ISSN:1687-8450
1687-8450
DOI:10.1155/2019/6084012